OptimizeRx Co. (NASDAQ:OPRX) Receives $15.86 Average Price Target from Analysts

OptimizeRx Co. (NASDAQ:OPRX) has been given an average recommendation of “Moderate Buy” by the six research firms that are covering the firm, Marketbeat reports. One analyst has rated the stock with a hold rating and five have given a buy rating to the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $15.86.

Several research firms recently commented on OPRX. Barclays started coverage on OptimizeRx in a research note on Wednesday, January 3rd. They set an “equal weight” rating and a $15.00 target price for the company. Royal Bank of Canada reissued an “outperform” rating and issued a $17.00 price objective on shares of OptimizeRx in a research note on Monday, April 1st. Stifel Nicolaus restated a “buy” rating and issued a $13.00 target price on shares of OptimizeRx in a report on Monday, April 1st. Finally, JMP Securities began coverage on OptimizeRx in a report on Thursday, April 4th. They issued a “mkt outperform” rating and a $15.00 target price on the stock.

Hedge Funds Weigh In On OptimizeRx

Hedge funds have recently made changes to their positions in the stock. Captrust Financial Advisors grew its position in shares of OptimizeRx by 248.8% in the second quarter. Captrust Financial Advisors now owns 1,287 shares of the company’s stock valued at $35,000 after purchasing an additional 918 shares in the last quarter. Point72 Hong Kong Ltd purchased a new position in shares of OptimizeRx in the first quarter valued at $52,000. UBS Group AG grew its position in shares of OptimizeRx by 290.0% in the third quarter. UBS Group AG now owns 1,997 shares of the company’s stock valued at $29,000 after purchasing an additional 1,485 shares in the last quarter. Nisa Investment Advisors LLC grew its position in shares of OptimizeRx by 215.0% in the fourth quarter. Nisa Investment Advisors LLC now owns 2,142 shares of the company’s stock valued at $31,000 after purchasing an additional 1,462 shares in the last quarter. Finally, Cetera Trust Company N.A purchased a new position in OptimizeRx during the fourth quarter worth about $77,000. 76.47% of the stock is currently owned by hedge funds and other institutional investors.

OptimizeRx Price Performance

NASDAQ OPRX opened at $10.76 on Friday. The business has a 50 day simple moving average of $13.79 and a 200 day simple moving average of $11.95. OptimizeRx has a one year low of $6.92 and a one year high of $16.65. The stock has a market capitalization of $195.29 million, a P/E ratio of -13.45 and a beta of 0.98.

OptimizeRx Company Profile

OptimizeRx Corporation, a digital health technology company, provides various solutions to life sciences organizations, healthcare providers (HCPs), and patients. Its products and applications include Evidence-Based Physician Engagement solution to assist HCPs in identifying patients who may be qualified for specific therapies, raise awareness of patient access pathways, and identify early indicators of non-adherence among patient populations; and Point of Care Banner messaging solution to deliver a variety of awareness and messaging within the clinical workflow.